News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Christopher T. Hoey, PharmD

Articles by Christopher T. Hoey, PharmD

Reasons Provided by Prescribers When Overriding Drug-Drug Interaction Alerts

ByAmy J. Grizzle, PharmD,Maysaa H. Mahmood, MS,Yu Ko, MS,John E. Murphy, PharmD,Edward P. Armstrong, PharmD,Grant H. Skrepnek, PhD,William N. Jones, MS,Gregory P. Schepers, PharmD,W. Paul Nichol, MD,Antoun Houranieh, PhD,Donna C. Dare, PharmD,Christopher T. Hoey, PharmD,Daniel C. Malone, PhD

October 1st 2007

Latest Updated Articles

Reasons Provided by Prescribers When Overriding Drug-Drug Interaction Alerts
Published: October 1st 2007 | Updated:

Trending on AJMC

TrumpRx Launch Brings Savings—and Uncertainty

How Do GLP-1 Agonists Fit Into Stroke Care?

Aligning Treatment Goals in IgA Nephropathy: Applying KDIGO’s Dual-Pathway Framework to Clinical Decision-Making

5 Things to Know About the Oral GLP-1 Era

Addressing Disparities at Every Step of the Stroke Care Pathway: Luke Messac, MD, PhD

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

© 2025 MJH Life Sciences^®

All rights reserved.

Alt Text

Alt Text